Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study.
Authors
Xin Qu
Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
Xin Qu , Xian Chen , Yong Li , Li-rong Liu , Yan-chun Qu , Fang-fang Hou , Wen-zhu Li , Yi-hong Liu , Yan-juan Zhu , Haibo Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05035914
DOI
10.1200/JCO.2022.40.4_suppl.TPS220
Abstract #
TPS220
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2012 Gastrointestinal Cancers Symposium
Early outcome of a phase I study of interrupted pulse dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer.
First Author: Eric Roeland
Poster
2024 ASCO Gastrointestinal Cancers Symposium
DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
First Author: Meredith Pelster
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Second-line bevacizumab plus FOLFOX in patients with metastatic colorectal cancer previously treated with adjuvant oxaliplatin-based chemotherapy.
First Author: Sang Hoon Chun